An AI-powered machine learning tool may allow physicians to better identify origins in enigmatic cancers, according to researchers at the Massachusetts Institute of Technology in Cambridge, Mass., and Dana-Farber Cancer Institute in Boston.
Oncology
Eleven newly named researchers will be the first group to embark on President Joe Biden's Cancer Moonshot, sharing $5.4 million in scholarships to "fight to end cancer as we know it," according to an Aug. 3 White House news release.
Cost-Saving Robotic Tech Bringing World-Class Care to >90% of Cancer Patients Who Currently Lack Access
Detroit-based Barbara Ann Karmanos Cancer Institute, a McLaren Health Care-owned facility, has named Boris Pasche, MD, PhD, as the center's new president and CEO, according to an Aug. 7 news release.
Three more cancer drugs are in short supply, according to the FDA and the American Society of Health-System Pharmacists.
Advertisement
Here are stories covering recent research, treatment, strategy and moves from some of the nation's top cancer hospitals:
While still in contract negotiations, registered nurses at Dana-Farber Cancer Institute - Merrimack Valley in Methuen, Mass., voted 33 to 1 to authorize a one-day strike, the Massachusetts Nurses Association said in an NBC Boston report.
Researchers at Los Angeles-based City of Hope recently announced promising results for a new chemotherapy pill that "appears to annihilate all solid tumors," according to research published Aug. 1 in Cell Chemical Biology.
The FDA approved GSK's Jemperli (dostarlimab) in combination with carboplatin and paclitaxel for adults with primary advanced or recurrent endometrial cancer who are mismatch repair deficient or microsatellite instability-high.
The University of Texas MD Anderson Cancer Center in Houston earned the No. 1 spot on U.S. News & World Report's "2023-24 Best Hospitals for Cancer" rankings, released Aug. 1.